In this episode titled “Lost in Translation”, we dive into the complex world of bringing cell therapies from the lab to human trials. With our guest Matthew Jeffers, author of a recent scoping review on this topic, we explore what regulators look for in promising cell therapies and why inconsistent guidelines can leave researchers unsure of their next steps. By summarizing expectations from various regulatory agencies worldwide, Jeffers et. al’s study offers a clearer blueprint for preclinical research, helping innovative treatments reach patients faster. Learn more: https://ca.linkedin.com/in/msjeffers0:05 | Introduction0:46 | Guest introduction1:24 | Why should we research the regulatory application process?3:05 | Reasons for the limited coordination between regulators, despite the existence of international health agencies.5:50 | How regulatory systems shift during exceptional circumstances, such as the COVID-19 pandemic, and the lessons that can be applied to improve the translation of future therapies.9:34 | The importance of placing a greater emphasis on understanding the regulatory landscape as scientific researchers and students.12:00 | Episode summaryBackground music "Embrace" by Evgeny_Bardyuzha, free for use under Pixabay's Content License.https://pixabay.com/music/electronic-embrace-364091/Hosts: Nicholas Lafond and Seb ParmasadPost-production & Content generation: Chloé McAllister, Mila Schaffrath, Nicholas Lafond, and Seb Parmasad

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related